Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Neoplasm, Residual 1Esophageal Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Cyclophosphamide 21Cytarabine 15blinatumomab 13fludarabine 12Azacitidine 10venetoclax 9fludarabine phosphate 9Blood Specimen Collection 8Methotrexate 7Lenalidomide 7Dexamethasone 7Rituximab 6Mercaptopurine 6Daunorubicin 6Vincristine 5daratumumab 4Whole-Body Irradiation 4Melphalan 4Etoposide 4Busulfan 4obinutuzumab 3Radiotherapy 3Neoadjuvant Therapy 3Maintenance 3Liquid Biopsy 3Immunotherapy, Adoptive 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasm, Residual × tetrathiomolybdate × Clear all
NCT06134375 2026-04-20

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Dartmouth-Hitchcock Medical Center

Phase 1/2 Recruiting
204 enrolled
Breast

Neoplasm, Residual, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡